410.1 The Effect of Steroid Pulse Therapy for the Reduction of Acute Rejection Episode in Subclinical Borderline Changes: An Open-Label, Randomized Clinical Trial
Dr. Eun Sung Jeong, Korea
410.2 Post-transplantation dynamics of non-HLA antibodies and early panel intensity as predictors of ABMR in kidney transplantation
Dr. Jinghong Tan, People's Republic of China
410.3 Anti-MICA Antibodies and Graft Outcomes in Kidney Transplant Recipients
Dr. Shubham Dubey, India
410.4 A prospective observational study to assess the role of donor derived cell free DNA (dd-cfDNA) in predicting active rejection in renal allograft recipients
Dr. Debdeep Mondal, India
410.5 Donor-derived cell-free DNA identifies subclinical antibody-mediated rejection in de novo donor-specific antibody-positive kidney transplant recipients
Prof. Ara Cho, Korea
410.6 Perioperative immunoabsorption in immunized kidney transplant recipients leads to higher graft survival rates
Dr. Paula van Appeldorn, Austria
410.7 Surveillance bronchoscopy: Key in early detection of acute cellular rejection in lung transplant recipients
Dr. Alonso J Marquez, United States
410.8 Our unique experience with low dose Alemtuzumab as induction agent in renal transplantation
Dr. Cherin Champannoor, India
410.9 Borderline (BL) rejection on renal recipients. Is steroid treatment enough to resolve it?